Answers are grounded in this paper and cite their sources.
Epidemiological study explores prevalence and risk factors of tendinopathies in primary care, highlighting treatment challenges.
Tendons are essential components of the musculoskeletal system, enabling movement by transmitting forces from muscles to bones while maintaining joint stability. Despite their vital function, tendons are susceptible to injuries and chronic conditions, collectively termed tendinopathies. These conditions, characterized by pain, functional impairment, and structural changes, affect diverse populations and present challenges in diagnosis, treatment, and prevention. These injuries represent a significant clinical and economic burden, causing a diminished quality of life. The talk will explore the biological and clinical aspects of tendon health and disease. Tendons, composed of a specialized extracellular matrix and tenocytes, are designed to withstand high mechanical loads. However, repetitive stress, aging, and metabolic dysfunction can disrupt tendon homeostasis, leading to inflammation, degeneration, and chronic pain. Current treatment modalities, including non-steroidal anti-inflammatory drugs, corticosteroids, and surgical interventions, often fail to resolve the condition fully and carry significant limitations. Eccentric exercise regimens, regenerative therapies, and biomarker-based diagnostics offer promising avenues for improved management. Furthermore, this presentation focuses on a retrospective epidemiological study of tendinopathies conducted in primary care centers across the Balearic Islands, Spain. The study analyzes ten years of clinical records to determine the prevalence, incidence, and risk factors of chronic tendinopathies, excluding traumatic injuries and acute cases. The findings provide crucial insights into the impact of these conditions within the local population and identify trends associated with demographic and lifestyle factors. Such data are essential for developing targeted prevention and treatment strategies. Acknowledgements: Carlos III Health Institute and the EU through the European Social Fund Plus for the Miguel Servet contract CP21/00136 and the project PI22/01686. TENET COST Action CA22170 for fostering collaboration and networking opportunities.
No takes yet. Share an insight, caveat, or question.
Manuel Gómez‐Florit (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: